177A
Kohjin Bio Co., Ltd.
コージンバイオ株式会社Kohjin Bio Co., Ltd. manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures. It also provides industrial cell cultures for CHO, hybridomas, and insect cells; exosome production; cryopreservation solutions; cell dissociation agents; adoptCell-NK kits, and bag and other materials. In addition, the company offers microbial mediums for clinical microbiology culture mediums, microbiology culture medium for food and environment, antimicrobial resistance test kits, and staining kits for microbiology; immunochromatographic assay kit; I-block series; and human blood, serum, and plasma. Further, it engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. Kohjin Bio Co., Ltd. was incorporated in 1981 and is headquartered in Sakado, Japan.
Price
¥1,007
Market Cap
¥5.1B
Ent. Value
¥4.0B
Net Cash
¥1.1B
Shares Out.
5.1M
P / E
6.4×
EV / EBIT
4.1×
P / Book
0.89×
P / NCAV
2.89×
Div. Yield
2.38%
Financials
| Metric |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
|---|---|---|
| Net Sales | ¥5.2B | ¥4.8B |
| Cost of Sales | ¥2.8B | ¥2.9B |
| Gross Profit | ¥2.4B | ¥1.9B |
| SG&A | ¥1.4B | ¥1.3B |
| Operating Income | ¥991M | ¥597M |
| Non-Operating Income | ¥118M | ¥94M |
| Dividend Income | ¥0M | ¥0M |
| Interest Income | ¥2M | ¥1M |
| Non-Operating Expenses | ¥44M | ¥55M |
| Interest Expense | ¥30M | ¥23M |
| Ordinary Income | ¥1.1B | ¥636M |
| Pre-tax Income | ¥1.0B | ¥636M |
| Income Taxes | ¥221M | ¥251M |
| Current Tax | ¥247M | ¥276M |
| Deferred Tax | ¥-26M | ¥-25M |
| Net Income (owners) | ¥795M | ¥385M |
| Comprehensive Income | ¥843M | ¥404M |
| EBITDA | ¥1.4B | ¥896M |
| EPS | ¥157.57 | ¥92.43 |
| Shares Outstanding | 5.1M | 4.2M |
| Shares Issued (total) | 5.1M | 4.2M |